Janssen Pharmaceutical Cos.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Janssen Pharmaceutical Cos.
Vaccine specialist SK Bioscience is set to launch potentially South Korea’s biggest biopharma IPO next month on the back of a growing premium vaccine business, new opportunities in COVID-19 vaccines and its contract manufacturing operations.
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
Public Company Edition: Among other recent large financings, BridgeBio Pharma launched a $650m note sale, CureVac closed a $517.5m follow-on offering and Revolution Medicines raised $260.9m.
Although South Korean pharma firms are largely sailing toward the common goal of globalization, they have different strategies to reach their goals. Scrip takes a look at the variety of paths being pursued.